{
  "docId": "019de514-c6ee-70fe-9ed1-115332e66453",
  "docSlug": "7d8148a830366811cd98c46e453c2fa7",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 10 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 10,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de514-c6ee-70fe-9ed1-115332e66453/8",
  "deckHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453",
  "deckJsonHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453.json",
  "deckAnchorHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.57,
        "w": 0.308,
        "x": 0.629,
        "y": 0.28
      },
      "kind": "image",
      "text": "Screenshot of a news article titled \"Drugmakers ask regulators to change standards on new Covid antibody drugs for most vulnerable\" by Jason Mast, Dec. 15, 2022.",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3edf0910-b3ab-48a0-a845-7bc010956a6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.576,
        "x": 0.046,
        "y": 0.354
      },
      "kind": "list",
      "text": "Neutralization is an accepted correlate of protection for next generation SARS-CoV-2 vaccine development\nMeta-analyses of clinical data support that neutralization potency is correlated with efficacy in prevention\nSerum titers achieved with passive administration of mAbs and active immunization with vaccines result in similar levels of protection\nNeutralization is the driver of efficacy against symptomatic COVID-19\nNext generation mAbs could be discovered and manufactured using technologies and processes used to produce previously authorized mAbs\nPrevious anti-SARS-CoV-2 mAbs have demonstrated a consistent, well tolerated safety profile\nStandardized neutralization assays and PK models could help establish protective titer thresholds",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccc20b97-4ba6-4095-b2e3-4d1cf8e6e580",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.576,
        "x": 0.046,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Multi-sponsor industry presentation provided scientific rationale for the use of surrogate clinical markers to support the development of next-generation RBD mAb products:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "490c0963-75e5-4a40-9420-aa2e1a4db2ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.034,
        "w": 0.576,
        "x": 0.046,
        "y": 0.928
      },
      "kind": "source-note",
      "text": "1. https://www.ema.europa.eu/en/events/joint-ema-fda-workshop-efficacy-monoclonal-antibodies-context-rapidly-evolving-sars-cov-2-variants\n2. https://www.ema.europa.eu/en/documents/agenda/agenda-joint-ema-fda-workshop-efficacy-monoclonal-antibodies-context-rapidly-evolving-sars-cov-2_en.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ae171bf-5c7e-4891-beaf-a0064b74aded",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.046,
        "y": 0.046
      },
      "kind": "title",
      "text": "FDA-EMA JOINT WORKING SESSION ON NOVEL STRATEGIES FOR COVID-19 ANTIBODY DEVELOPMENT IN THE FACE OF RAPIDLY EVOLVING VARIANTS – DECEMBER 20221,2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4553db2a-77cb-46f6-afa8-8a24ba6a8bc6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a7b72042-9d27-48d8-9817-06bc90958dd1",
      "evidence": "list/bullet: Neutralization is an accepted correlate of protection for next generation SARS-CoV-2 vaccine development",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 5,
      "beatId": "8f586047-fdbe-4793-9641-0c1f5c37eadc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation of Invivyd's combination approach and pipeline of antibodies",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}